Fortress Biotech, Inc. Quarterly report pursuant to Section 13 or 15(d)

Accrued Expenses and Other Long-Term Liabilities

3 Months Ended

Mar. 31, 2018

12. Accrued Expenses and Other Long-Term Liabilities

Accrued expenses and other long-term liabilities, excluding National, consisted of the following:

	March 31, 2018		December 31, 2017
Accrued expenses:
Professional fees	$	1,497	$	1,625
Salaries, bonuses and related benefits		6,002		5,279
Accrued expenses - related party		107		95
Research and development		7,061		4,046
Dr. Falk Pharma milestone (See Note 16)		3,059		3,059
Accrued royalties payable		1,091		1,411
Accrued coupon expense		735
Deferred coupon funding		1,516		1,087
Other		646		1,030
Total accrued expenses	$	21,714	$	17,632

Other long-term liabilities:
Deferred rent		4,759		4,739
Total other long-term liabilities	$	4,759	$	4,739

National's accounts payable and other accrued expenses as of December 31, 2017 and September 30, 2017, consisted of the following: